Avraham Pharmaceuticals Announces Commencement of a Phase 2 Study of Ladostigil for the Treatment of MCI

by Blog Burger on May 17, 2012

Enrollment has been completed in a Phase 2 study of ladostigil for the treatment of Alzheimer’s Disease and results expected in Q4 2012 Yaacov Michlin appointed Chairman of the Board and Dr. Yona Geffen appointed Chief Executive Officer YAVNE, Israel–(BUSINESS WIRE)–Avraham Pharmaceuticals Ltd. announced today the commencement of a Phase 2 clinical trial to evaluate the safety and efficacy of ladostigil in patients diagnosed with mild cognitive impairment (MCI). This 36-month, multi-centre, randomized, double-blind, placebo-controlled trial will include at least 200 patients in 16 centers in Europe and Israel. “I am delighted to lead Avraham in these exciting times for the company,…

WN.com – Science News

Comments on this entry are closed.

{ 322 trackbacks }

Previous post:

Next post: